New immunotherapy targets for estrogen-receptor positive breast cancer
Part of Cancer clinical trials.
This trial tests a new technique to find unique targets on breast cancer cells that could be used for future immunotherapies. It focuses on women with estrogen-receptor positive primary breast cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman.
- You are at least 18 years old.
- You have been diagnosed with estrogen-receptor positive breast cancer.
- This breast cancer is your first and only tumor (primary, not a recurrence or spread).
- You have not had any other type of cancer before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of radiation therapy that targets a specific protein on some breast cancer cells. It may help people whose cancer has stopped responding to other treatments.
This trial tests two immunotherapy drugs (atezolizumab and tiragolumab) for people with advanced triple-negative breast cancer that has not responded to standard treatments. It aims to see if this combination can shrink or slow the cancer.
This Phase 2 study tests a combination of immune-based treatments along with hormone (endocrine) therapy to slow or shrink advanced, hormone-receptor positive, HER2-negative breast cancer. You may be a candidate if your cancer has progressed after standard hormone-blocking medicines and you can start treatment with CDK4/6 medicine plus an aromatase inhibitor.
This study tests a new treatment for advanced HER2-negative breast cancer. Doctors will take immune cells from lymph nodes near your tumor, grow them in a lab, and then give them back to you along with chemotherapy and immunotherapy. This approach aims to help your body fight the cancer more effectively.
This trial tests a combination of an immunotherapy drug (QL1706) plus standard chemotherapy given before surgery to shrink triple-negative breast cancer. The goal is to see if this approach helps remove the tumor more completely.
This trial is testing a new treatment approach for patients with a certain type of breast cancer (HR+/HER2-). It combines radiation therapy with chemotherapy and an immunotherapy drug before the patient's main surgery, to see if it can shrink or eliminate the tumor more effectively.
Hear when a new Estrogen-receptor-positive Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.